{"id":189995,"date":"2024-05-24T17:23:02","date_gmt":"2024-05-24T22:23:02","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/05\/car-t-cell-therapy-targeting-her2-antigen-shows-promise-against-advanced-sarcoma-in-phase-i-trial"},"modified":"2024-05-24T17:23:02","modified_gmt":"2024-05-24T22:23:02","slug":"car-t-cell-therapy-targeting-her2-antigen-shows-promise-against-advanced-sarcoma-in-phase-i-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/05\/car-t-cell-therapy-targeting-her2-antigen-shows-promise-against-advanced-sarcoma-in-phase-i-trial","title":{"rendered":"CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I trial"},"content":{"rendered":"

<\/a><\/p>\n

Researchers at Texas Children\u2019s Cancer Center<\/a> and the Center for Cell and Gene Therapy<\/a> at Baylor College of Medicine<\/a>, Texas Children\u2019s Hospital<\/a> and Houston Methodist<\/a> published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer<\/em><\/a>.<\/p>\n

The therapy uses chimeric antigen receptor (CAR) T cells engineered to target the HER2 protein, which is overexpressed on the surface of sarcoma cells. Sarcoma is a type of solid cancer that develops in the bones and soft tissues. The HEROS 2.0 trial showed that this therapeutic approach is safe and is associated with clinical benefit.<\/p>\n

\u201cCAR T cell therapy has been a highly successful strategy for recurrent or high-risk leukemias or lymphomas, but challenges remain in using this therapy for solid tumors,\u201d said first and corresponding author Dr. Meenakshi Hegde<\/a>, associate professor of pediatrics<\/a> \u2013 hematology and oncology<\/a> at Baylor and pediatric oncologist at Texas Children\u2019s Cancer Center. \u201cThe results of this trial show that we are moving the dial in harnessing the power of CAR T cells as an effective anticancer therapy for sarcomas.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Researchers at Texas Children\u2019s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children\u2019s Hospital and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer. The therapy uses chimeric antigen receptor (CAR) T cells engineered [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-189995","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/189995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=189995"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/189995\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=189995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=189995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=189995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}